DNX-5000 series

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug NameDNX-5000 series
Drug Alias Namedual FAK/PYK2 kinase inhibitors (Dynamix)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFocal adhesion kinase 2 inhibitors
TargetsFocal adhesion kinase 2
Therapy Area/IndicationsOsteoporosisMultiple MyelomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesDynamix Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDynamix Pharmaceuticals Ltd
Active IndicationsN/A
Inactive IndicationsOsteoporosisMultiple MyelomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A